SLC44A2 and adrenal cortex carcinoma: In contrast, patients with lower SLC44A2 expression in pancreatic adenocarcinoma (PAAD), invasive breast carcinoma (BRCA), and adrenocortical carcinoma (ACC) had better OS than those with higher SLC44A2 expression (Fig. S1D).